GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II... The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.
- Mechanism
- Curator reviewed
GTI-2501 is an antisense oligonucleotide complementary to the R1 component of ribonucleotide reductase, which component is essential for DNA replication and tumor cell proliferation. GTI-2501 is designed to exert its activity by specific downregulation of the R1 component of ribonucleotide reductase. In preclinical studies, GTI-2501 showed significant antitumor activity against prostate cancer and a variety of other tumor types including colon, pancreas, NSCLC, breast, ovary, melanoma, brain (glioblastoma-astrocytoma), renal, cervical, lymphoma and leukemia.
- Primary indication
- Investigated for use/treatment in prostate cancer and solid tumors.Curator reviewed
- Code names
- GTI-2501
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with GTI-2501, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account